StreetInsider.com News Articles

Form 4 Neurogene Inc. For: Jul 06 Filed by: Cvijic Christine Mikail

Tue, 07 Jul 2026 21:08:00 -0400

si-local-file:///var/storage/secattach/20260707/26743119.html

Form 4 Neurogene Inc. For: Jul 06 Filed by: Cvijic Christine Mikail

Tue, 07 Jul 2026 21:08:00 -0400

si-local-file:///var/storage/secattach/20260707/26743119.html

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 06 Jul 2026 16:01:00 -0400

NEW YORK--(BUSINESS WIRE)-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 96,450 shares of the Company’s common stock to six new employees (the “Inducement Grants”) on July 6, 2026 (the “Grant Date”). The Inducement Grants have been granted pursuant to the Company’s 2025 Inducement Plan. The Inducement Grants were granted as an inducement material to these individuals entering into

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 06 Jul 2026 16:01:00 -0400

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 06 Jul 2026 16:01:00 -0400

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 06 Jul 2026 16:01:00 -0400

Form 4 Neurogene Inc. For: Jul 01 Filed by: Cvijic Christine Mikail

Thu, 02 Jul 2026 18:43:00 -0400

si-local-file:///var/storage/secattach/20260702/26729997.html

Form 4 Neurogene Inc. For: Jul 01 Filed by: Cvijic Christine Mikail

Thu, 02 Jul 2026 18:43:00 -0400

si-local-file:///var/storage/secattach/20260702/26729997.html

Form 424B5 Neurogene Inc.

Thu, 02 Jul 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260702/26723470.html

Form 424B5 Neurogene Inc.

Thu, 02 Jul 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260702/26723470.html

Form 8-K Neurogene Inc. For: Jun 30

Thu, 02 Jul 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260702/26723475.html

Form 8-K Neurogene Inc. For: Jun 30

Thu, 02 Jul 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260702/26723475.html

Taysha Gene Therapies (TSHA) Reiterated at Market Outperform by Citizens

Thu, 02 Jul 2026 04:19:24 -0400

Citizens analyst Silvan Tuerkcan reiterated a Market Outperform rating and $11.00 price target on Taysha Gene Therapies (NASDAQ: TSHA).

The analyst commented, "Overall, we come away positive from the meeting for TSHA-102 and recommend the stock ahead of pivotal data and regulatory feedback in 1H27. At a high level, attendees were convinced by the early results, with an emphasis on improved communication and grasping, which have a very high impact on QoL. "How can we compare pivotal efficacy across programs?" remained unanswered. To our surprise, doctors at centers of excellence and patients did not mind Neurogene's (NGNE, NC) more-involved ICV delivery

Taysha Gene Therapies (TSHA) Reiterated at Market Outperform by Citizens

Thu, 02 Jul 2026 04:19:24 -0400

Citizens analyst Silvan Tuerkcan reiterated a Market Outperform rating and $11.00 price target on Taysha Gene Therapies (NASDAQ: TSHA).

Neurogene (NGNE) PT Raised to $77 at Leerink

Wed, 01 Jul 2026 14:38:52 -0400

Leerink analyst Mani Foroohar raised the price target on Neurogene (NASDAQ: NGNE) to $77.00 (from $70.00) while maintaining a Outperform rating.

The analyst comments "● Bottom Line: Following positive Ph1/2 NGN-401 Rett syndrome update (note here), NGNE announced pricing of an underwritten public offering of 3.5mm common shares at $30.00/share and pre-funded warrants to purchase up to 666,666 shares at ~$30 each (exercise price of $0.000001/share), for aggregate gross proceeds of ~$125mm before underwriting discounts and offering expenses. The company also granted underwriters a 30-day option to purchase up to an additional 624,999 common shares, implying potential additional gross proceeds of

Neurogene (NGNE) PT Raised to $77 at Leerink

Wed, 01 Jul 2026 14:38:52 -0400

Leerink analyst Mani Foroohar raised the price target on Neurogene (NASDAQ: NGNE) to $77.00 (from $70.00) while maintaining a Outperform rating.

Neurogene prices $125 million public offering at $30 per share

Wed, 01 Jul 2026 07:00:20 -0400